CTOs on the Move

Scout.com Inc

www.scout.com

 
Scout.com Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.scout.com
  • 2003 Western Ave Ste 700
    Seattle, WA USA 98121
  • Phone: 888.979.0979

Executives

Name Title Contact Details

Similar Companies

IMV technologies USA

The IMV Technologies Group is a leader in the areas of animal and human assisted reproduction technologies and veterinary imaging. IMV Technologies provides customers with solutions for animal artificial insemination; its human division, Cryo Bio System, offers solutions for human assisted reproduction including human embryo vitrification, human sperm freezing and preservation and other assisted reproduction technologies. The IMV imaging business provides customers with veterinary imaging solutions.

Fortis Life Sciences

Fortis Life Sciences offers word-class reagents, tools, materials, and custom services for our research, diagnostic and therapeutic customers. Learn more here.

Pharmadule

Pharmadule is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tetra Bio-Pharma

Tetra Bio-Pharma is a multi subsidiary publicly traded company engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Inflammatix

Inflammatix, Inc. is a venture-backed startup located in the San Francisco Bay Area that is building novel diagnostics for acute infections and sepsis based on our unique immune biomarkers. Approximately $10 billion / year is spent trying to diagnose acute infections, but current technologies that focus on `finding the bug` are (1) slow and (2) effective in fewer than 30% of cases. Inflammatix has developed a statistically rigorous, extensively validated diagnostic method that `reads` the immune system. Our HostDx™ tests report clinically actionable information on the presence, type (bacterial or viral), and severity of infection in all patients. They have been extensively validated and published in top-tier medical journals. After this initial product, Inflammatix plans to develop and commercialize additional novel diagnostic tests to address significant unmet clinical needs.